Evidence map›Paper›PMID 42620472›Full record

ArticleFrontiers in physiology2026

Evaluating the analgesic effect of metamizole in the mouse model for DSS-induced acute colitis.

D T Jacob, L M Keubler, A Glasenapp, K Selke, M Buettner, L Wenzel, S Buchheister, S Lutscher, H Bähre, M Bankstahl and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

D T JacobInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
L M KeublerInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
A GlasenappInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
K SelkeInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
M BuettnerInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
L WenzelInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
S BuchheisterInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
S LutscherInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
H BähreResearch Core Unit Metabolomics, Hannover Medical School, Hannover, Germany.
M BankstahlInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
A BleichInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.
C HägerInstitute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A commonly used mouse model of ulcerative colitis is the Dextran Sodium Sulphate (DSS) colitis model, including symptoms of weight loss, softening of stool up to diarrhea, and abdominal pain. To address 3R-refinement, we aimed to reduce severity in this model through pain therapy with metamizole. In addition to the potential analgesic effect, we investigated whether metamizole had a modulatory effect on inflammatory processes. In the study, ten-week-old female C57BL/6J mice were used. For pharmacological analysis, mice were treated with 200 mg/kg/d metamizole over 2 days to calculate baseline plasma concentration of metamizole metabolites using LC-MS/MS. After 14 days, DSS was administered via drinking water for 5 days, followed by metamizole for 2 days to determine plasma concentration. To assess disease severity and pain therapy, mice received DSS via drinking water for 5 days, controls received water only. Mice were then treated with metamizole via the drinking water for an additional 5 days, while corresponding sub-cohorts were left untreated (water+water, water+metamizole, DSS+water, DSS+metamizole). For severity assessment, changes in bodyweight, posture, stool consistency, voluntary wheel running (VWR) and Mouse Grimace Scale (MGS) were analyzed. Furthermore, colon samples were used for histology and gene expression analyses. LC-MS/MS analysis revealed significantly higher plasma concentrations of 4-methylaminoantipyrine and increased concentrations of 4-aminoantipyrine following DSS and subsequent metamizole treatment when compared to baseline. Assessing disease severity in control mice (water+water or water+metamizole-treated) demonstrated no clinical signs or changes in VWR. DSS+water and DSS+metamizole treated mice showed similar loss of body weight and clinical signs. VWR performances were decreased in DSS+water-treated mice as well as in DSS+metamizole-treated mice. There were no statistically significant differences between untreated and metamizole-treated animals with DSS-colitis. Interestingly, none of the groups showed elevated MGS scores, nor did the gene expression analyses detect relevant differences. This study showed that administering metamizole via drinking water led to detectable levels of metamizole metabolites in the plasma of treated mice. However, metamizole did not reduce disease severity or pain in this mouse model. Therefore, other refinement strategies should be explored in future studies.

Indexed as

4-AA4-MAAanalgesiaIBDmetamizolerefinementseverity assessmentwheel running

Identifiers

PMID42620472
PMCPMC13485539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.